Liquidia (NASDAQ:LQDA) Insider Sells $353,771.40 in Stock
by Scott Moore · The Cerbat GemLiquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Rajeev Saggar sold 9,220 shares of the stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $38.37, for a total transaction of $353,771.40. Following the completion of the transaction, the insider directly owned 173,270 shares in the company, valued at $6,648,369.90. The trade was a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Liquidia Stock Performance
Shares of NASDAQ LQDA traded down $0.14 during mid-day trading on Tuesday, reaching $38.71. 844,813 shares of the company were exchanged, compared to its average volume of 1,775,539. The stock has a market capitalization of $3.41 billion, a P/E ratio of -46.64 and a beta of 0.45. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. The company’s 50-day simple moving average is $36.87 and its 200-day simple moving average is $32.92. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $46.67.
Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business’s revenue for the quarter was up 3072.4% on a year-over-year basis. As a group, research analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on LQDA shares. HC Wainwright increased their target price on Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Wells Fargo & Company upped their price objective on Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a report on Monday, March 23rd. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Needham & Company LLC lifted their target price on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.44.
View Our Latest Research Report on LQDA
Institutional Investors Weigh In On Liquidia
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the fourth quarter valued at approximately $25,000. NewEdge Advisors LLC bought a new position in Liquidia during the 2nd quarter worth $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Liquidia in the 3rd quarter valued at $30,000. FNY Investment Advisers LLC acquired a new position in Liquidia in the 3rd quarter valued at $34,000. Finally, Covestor Ltd lifted its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.
Liquidia Company Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).